Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25)
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25). // International Journal of Gynecological Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1048891X26012338?dgcid=rss_sd_all
Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25). International Journal of Gynecological Cancer. https://www.sciencedirect.com/science/article/pii/S1048891X26012338?dgcid=rss_sd_all
“Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25).” International Journal of Gynecological Cancer.
@article{article100382,
title = {Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25)},
journal = {International Journal of Gynecological Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1048891X26012338?dgcid=rss_sd_all}
}